1. inability to comprehend and to follow all required study procedures. 2. have a recent history (documented, confirmed or suspected) of a flu-like disease within a week of vaccination. 3. have a known allergy to polyethylene glycol (peg) or other components of the study vaccines, or history of any anaphylaxis, serious vaccine reactions, to any excipients. 4. have known active human immunodeficiency virus (hiv) infection. 5. received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. 6. tympanic temperature ≥ 38°c within 3 days of intended study vaccination 7. have a history of alcohol or drug abuse in the last 5 years. 8. have any condition that the investigator believes may interfere with successful completion of the study

1. inability to comprehend and to follow all required study procedures. 2. have a recent history (documented, confirmed or suspected) of a flu-like disease within a week of vaccination. 3. have a known allergy to polyethylene glycol (peg) or other components of the study vaccines, or history of any anaphylaxis, serious vaccine reactions, to any excipients. 4. have known active human immunodeficiency virus (hiv) infection. 5. received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. 6. tympanic temperature ≥ 38°c within 3 days of intended study vaccination 7. have a history of alcohol or drug abuse in the last 5 years. 8. have any condition that the investigator believes may interfere with successful completion of the study

inability to comprehend and to follow all required study procedures. have a recent history (documented, confirmed or suspected) of a flu-like disease within a week of vaccination. have a known allergy to polyethylene glycol (peg) or other components of the study vaccines, or history of any anaphylaxis, serious vaccine reactions, to any excipients. have known active human immunodeficiency virus (hiv) infection. received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. tympanic temperature ≥ 38°c within 3 days of intended study vaccination have a history of alcohol or drug abuse in the last 5 years. have any condition that the investigator believes may interfere with successful completion of the study

inability to comprehend and to follow all required study procedures. have a recent history (documented, confirmed or suspected) of a flu-like disease within a week of vaccination. have a known allergy to polyethylene glycol (peg) or other components of the study vaccines, or history of any anaphylaxis, serious vaccine reactions, to any excipients. have known active human immunodeficiency virus (hiv) infection. received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. tympanic temperature ≥ 38°c within 3 days of intended study vaccination have a history of alcohol or drug abuse in the last 5 years. have any condition that the investigator believes may interfere with successful completion of the study